The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19

Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Marcos, Paixão, Enny, Trajman, Anete, de Souza, Ramon Andrade, da Natividade, Marcio Santos, Pescarini, Julia M., Pereira, Susan Martins, Barreto, Florisneide Rodrigues, Ximenes, Ricardo, Dalcomo, Margareth, Ichihara, Maria Yury, Nunes, Ceuci, Barral-Netto, Manoel, Barreto, Maurício L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7351640/
https://www.ncbi.nlm.nih.gov/pubmed/32653040
http://dx.doi.org/10.1186/s12931-020-01439-4
Descripción
Sumario:Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.

Ejemplares similares